3928 Point Eden Way
About Arcus Biosciences
Arcus is clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities. Since our inception in 2015, we have built a broad portfolio of small-molecule and antibody product candidates that we plan to develop together as intra-portfolio combinations. We have initiated clinical trials for our two most advanced product candidates, both of which are expected to generate data in 2018, and we expect clinical data from our first intra-portfolio combinations in the first half of 2019.
Stock Symbol: RCUS
Stock Exchange: NYSE
31 articles with Arcus Biosciences
Arcus Biosciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Updates
Ended 2018 with four molecules in clinical development, including AB928, the Company’s dual A2aR/A2bR receptor antagonist, which is being evaluated in several dose-escalation trials in combination with chemotherapy or AB122 (anti-PD-1 antibody)
Arcus Biosciences Announces Upcoming Presentations at the 2019 American Association for Cancer Research Annual Meeting
Seven presentations at the 2019 American Association for Cancer Research (AACR) Annual Meeting being held March 29-April 3, 2019 in Atlanta, Georgia.
Arcus Biosciences Announces Participation at Upcoming Investor Conference on Wednesday, February 27, 2019
Arcus Biosciences, Inc. announced that Terry Rosen, Ph.D., Chief Executive Officer, will participate in a fireside chat at the 8th Annual Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019 at 11:30 am ET at the Lotte New York Palace, in New York, NY.
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Jennifer Jarrett will step down as the Company’s Chief Financial and Operating Officer, effective January 11, 2019, to pursue an opportunity at a privately-held transportation and technology company.
Arcus Biosciences Presents Initial Data from the Phase 1 Dose-Escalation Study of AB122, its anti-PD-1 antibody, at the SITC 2018 Annual Meeting
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced preliminary data from its ongoing Phase 1 dose-escalation study of AB122.
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced financial results for the third quarter ended September 30, 2018 and provided updates on its clinical and preclinical programs. “
Arcus Biosciences, Inc. today announced that members of the management team will participate at the following upcoming investor conferences:
Dr. Hege brings more than 20 years of oncology clinical leadership experience to Arcus’s board.
Taiho Ventures, the corporate venture capital arm of Taiho Pharmaceutical, has pumped up its venture capital pool from $50 million to $300 million. It also indicates it plans to accelerate its “open innovation” through the investments.
Arcus Biosciences to Present Final Results from the Phase 1 Study of AB928 in Healthy Volunteers at ESMO 2018 Congress
Arcus Biosciences, Inc. today announced that it will present final results from the Phase 1 study of AB928, its dual adenosine receptor antagonist, in healthy volunteers during a poster display session at the European Society of Medical Oncology (ESMO) 2018 Congress, being held October 19-23, 2018, in Munich, Germany.
Initiated the Phase 1/1b program for AB928 combinations; Initial dose-escalation data for all four combinations expected in the first half of 2019
Arcus Biosciences, Inc. will participate in a fireside chat at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14, 2018 at 2:30 pm ET at the Parker New York, in New York City, NY.
Arcus Biosciences, Inc. announced that it has received regulatory approval to initiate its Phase 1 trial for AB154
AB928 was safe and well tolerated at all doses evaluated
Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories
Arcus Biosciences, Inc. announced that Taiho Pharmaceutical Co., Ltd. exercised its option under the Option and License Agreement entered into in September 2017 (Taiho Agreement) to obtain an exclusive development and commercialization license to the Company’s adenosine receptor antagonist program
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.
Ms. Jarrett will be responsible for several key areas, including finance, investor relations, corporate communications, business and corporate development, strategic planning and human resources.
Arcus Biosciences Announces FDA Clearance of INDs for AB928 and AB122 and Initiation of Phase 1/1b Program to Evaluate AB928 Combinations
Phase 1/1b trial to evaluate the safety, tolerability and preliminary efficacy in patients with breast and gynecologic malignancies.
CEO "extremely encouraged by the results from our ongoing Phase 1 trial of AB928."
Arcus Biosciences announced that five abstracts have been accepted for poster presentation at the American Association for Cancer Research (AACR) 2018 Annual Meeting to be held April 14-18, 2018 in Chicago, Illinois.